Skylark Bio
Cambridge, US · Founded 2021 · Delaware corporation · 20 employees on LinkedIn · 1 known investors
Boston-area biotech developing gene therapies for genetic causes of pediatric hearing loss.
Also known as Skylark Bio, Inc.
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$40.9M disclosed across 1 of 2 rounds · 2022–2026
▶$40.9MraisedApr 2024 · 2 investors · BiotechnologyRule 506(b)
- Steve GillisDirector
- Giampiero De LucaDirector
- Jodi A. CookExecutive Officer, Director
- Will McLeanExecutive Officer
- Offering amount
- $40.9M
- Amount sold
- $40.9M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Skylark Bio, Inc. is a gene therapy company working on treatments that address genetic causes of hearing impairment, with the stated aim of improving patient outcomes and quality of life [0]. Company profiles describe it as founded in 2021 and based in Massachusetts, United States, with fewer than 10 employees as of a February 2026 profile update [1]. It is characterized in industry coverage as a Boston-based gene therapy developer [1].
The company has been described as preclinical, with its chief executive characterized as "the preclinical biotech CEO of a gene therapy company focused on curing pediatric deafness" [4]. As of January 2026, an investor in the company stated that Skylark was entering a clinical trial enrolling 10 children with an experimental medicine for pediatric hearing loss [1].
Business model
Skylark Bio is a therapeutics developer funded by venture capital rather than by product sales; the available sources describe research and development of gene therapy candidates and progression toward clinical testing, with no disclosed commercial products or revenue [0][1][4].
Traction
As of January 2026, the company was reported to be entering a 10-child clinical trial of an experimental medicine for pediatric hearing loss, and its website stated that ARCH Venture Partners had led $60 million in funding for the company [1]. A drug-database profile notes fewer than 10 employees and no listed medical patents associated with the company as of February 2026 [1].
Latest developments
In January 2026, Israel-based Arkin Capital disclosed that it had participated in a financing for Skylark Bio as the first investment from its $100 million Arkin Bio Ventures III fund, and stated that the company was entering a 10-child clinical trial for pediatric hearing loss; the same report cited the company's website as saying ARCH Venture Partners had led $60 million in funding [1].
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Skylark Bio is an early-stage, seed-stage-classified biotech in the biotech and life sciences sector [0]. A startup directory lists Skyhawk Therapeutics, Dyne Therapeutics, Siren Bio, Dyno Therapeutics, and Encoded Therapeutics as similar companies [0].
Technology
The company develops gene therapies targeting the genetic causes of hearing impairment [0], with a lead experimental medicine for pediatric hearing loss described as entering a small clinical trial in children [1].
Go-to-market
Patients with genetic hearing impairment, with the initial clinical focus on children with pediatric hearing loss [0][1][4].
Geography
Headquartered in Massachusetts, United States, and described in press coverage as Boston-based [1].
History
Company profiles date Skylark Bio's founding to 2021 in Massachusetts [1]. Jodi Cook, PhD, serves as President and CEO; she previously was Senior Vice President of Gene Therapy Strategy at PTC Therapeutics and founding Chief Operating Officer of Agilis Biotherapeutics, where she oversaw its $1 billion acquisition, and she holds a PhD from Arizona State University, a Master's in Audiology from the University of South Carolina, and a BA from Loyola University Maryland, with a fellowship at Johns Hopkins Medical School [4].
Risks & controversies
The sources note the company is very small (fewer than 10 employees) and at an early development stage entering a small first clinical trial, and its CEO has publicly described operating a biotech in a challenging funding climate [1][4]. No controversies are reported in the available sources.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsArkin Capital, an Israel-based investor, said it took part in a financing for Boston gene therapy developer Skylark Bio; the investment was described as the first from its newly closed $100 million Arkin Bio Ventures III fund, which writes roughly $10 million seed and Series A checks.
An investor stated that Skylark Bio is entering a clinical trial enrolling 10 children with an experimental medicine for pediatric hearing loss.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 5
primary sources listed
- Skylark Bio — Biotech & Life Sciencesf4.fund · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Skylark Bio do?
- Boston-area biotech developing gene therapies for genetic causes of pediatric hearing loss.
- Who are Skylark Bio's investors?
- Skylark Bio's investors include ARCH Venture Partners.
- How much funding has Skylark Bio raised?
- Skylark Bio has disclosed $40.9M raised across 1 of its 2 known rounds.
- Where is Skylark Bio headquartered?
- Skylark Bio is headquartered in Cambridge, US.